4
Changes in Ownership
CytomX Therapeutics, Inc. Filed Acc 0001140361-18-012009
Chief Financial Officer sold 33,000 shares at an average $29.99 ($989,694)
- Chief Financial Officer acquired 33,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| RAY DEBANJAN Chief Financial Officer | 2018-03-01 | Option exercise | +13,000 | $1.26 | $16,379 | 17,741 | D |
| RAY DEBANJAN Chief Financial Officer | 2018-03-01 | Sale | −13,000 | $29.40 | $382,242 | 4,741 | D |
| RAY DEBANJAN Chief Financial Officer | 2018-03-02 | Option exercise | +5,515 | $1.26 | $6,948 | 10,256 | D |
| RAY DEBANJAN Chief Financial Officer | 2018-03-02 | Sale | −5,515 | $30.06 | $165,775 | 4,741 | D |
| RAY DEBANJAN Chief Financial Officer | 2018-03-02 | Option exercise | +14,485 | $1.13 | $16,425 | 19,226 | D |
| RAY DEBANJAN Chief Financial Officer | 2018-03-02 | Sale | −12,541 | $30.41 | $381,384 | 6,685 | D |
| RAY DEBANJAN Chief Financial Officer | 2018-03-02 | Sale | −1,944 | $31.02 | $60,293 | 4,741 | D |
| Derivatives | |||||||
| RAY DEBANJAN Chief Financial Officer | 2018-03-01 | Option exercise · Stock Option (Right to Buy) | −13,000 | 20,225 | D | ||
| RAY DEBANJAN Chief Financial Officer | 2018-03-02 | Option exercise · Stock Option (Right to Buy) | −5,515 | 14,710 | D | ||
| RAY DEBANJAN Chief Financial Officer | 2018-03-02 | Option exercise · Stock Option (Right to Buy) | −14,485 | 20,000 | D | ||
| Open-market sales · 33,000 sh · avg $29.99 · $989,694 | |||||||
Loading xslF345X03/doc1.xml…